Shanghai-based SciBrunch Therapeutics, a developer of small molecule anti-tumor drugs, has reportedly secured over RMB 200 million (USD 28 million) in an angel financing round. The funding was co-led by BioTrack Capital and Hankang Capital, with participation from Elikon Venture and LongRiver Investments.
Funding and Objectives
The proceeds from this financing round will be utilized to advance the company’s pre-clinical and clinical studies. This injection of capital supports SciBrunch Therapeutics’ mission to develop innovative treatments in the oncology space.-Fineline Info & Tech
